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Injections are one of the most common health care procedures. According to 
WHO data, there are 16 billion medical injections performed annually in developing and 
transitional countries. In countries where unnecessary injections are common, the average 
number of injections per person has been estimated to be 3.7 per year and half of them 
are estimated to be unsafe injections (Hauri AM et al., 2003).  
Each year, reuse or unsafe practice of injection devices may cause 20 million 
infections with hepatitis B virus (HBV), 2 million infections with hepatitis C virus 
(HCV), and 250,000 infections with human immunodeficiency virus (HIV) worldwide. 
Like many developing countries, unsafe injection practices are a significant issue for 
Central Asian countries of Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and 
Uzbekistan. In addition to unsafe injections, overuse of transfusions of blood and blood 
products, reuse of single use medical equipment, inadequate sterilization, improper 
disposal of sharps (e.g., needles, scalpel blades, etc.) are also major cause of concern in 
Central Asia.    
The term “injection safety” was initially used when it was recognized that 
injections—which are typically thought of as being intramuscular—may be an important 
mode of transmission of HIV or hepatitis viruses.  More recently, the term has been 
broadened to include other means of parenteral injection of substances (intravenously), 
withdrawing of blood (phlebotomy) or for intravenous/intra-arterial access (catheters in 
veins or arteries).   
WHO’s definition of safe injections is:  A safe injection, phlebotomy, lancet 
procedure or intravenous device insertion does not harm the recipient, does not expose 
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the provider to any avoidable risk and does not result in any waste that is dangerous for 
other people.” 
The HIV epidemic in Central Asian Republics of Kazakhstan, Kyrgyzstan, 
Tajikistan, Turkmenistan, and Uzbekistan is primarily driven by injecting drug users 
(IDUs), however, Ministries of Health (MoHs) estimate that anywhere between 2-15% of 
the HIV transmissions occur due to nosocomial infections. However, lack of proper 
monitoring and evaluation systems in the region have led many to believe that a larger 
proportion of HIV transmission is caused by nosocomial infection in Central Asia.  
The first HIV outbreak in the region occurred in 2006 when more than 130 
children were infected with HIV in Shymkent, Kazakhstan. Outbreak investigation 
conducted by the Centers for Disease Control and Prevention (CDC) cited intravenous 
route of medication, subclavian vein catherization, and use of blood or blood products as 
the main risk factors for HIV transmission.  
In early 2007, another HIV outbreak was reported in Osh, Kyrgyzstan, where 
initially it was reported that at least 26 people, mostly children, acquired HIV infection in 
two local hospitals. CDC was asked again to conduct an investigation and estimated that 
the number of children infected exceeded 100. The results of the investigation cited 
intramuscular and intravenous injections to be the primary risk factor for HIV 
transmission as well.  Data from the CDC outbreak investigation is presented below. 
Also in 2007, HIV outbreak was reported in Andijan, Uzbekistan among 7 
children; however, the government never confirmed the outbreak. Although no evidence 
exists it is believed that nosocomial infection was the primary cause of the outbreak.  
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Subsequently, in November 2008, BBC reported that more than 40 children were 
infected with HIV in Namangan, Uzbekistan. Uzbek government did not request CDC to 
investigate the outbreak, however, a team of UN agencies, including UNAIDS, UNICEF, 
and WHO, visited Namangan on a fact finding mission. UN agencies reported unsafe 
injection practices to be the primary risk factor for HIV transmission among children. 
Then, in March 2010, an Uzbek documentary was leaked to the media that claimed more 
than 147 children were infected with HIV between 2007 and 2008 in Namangan alone.  
After each of the outbreak that CDC investigated, CDC provided training to 
physicians and healthcare workers on proper injecting techniques, however, it was 
evident that localized trainings or interventions would not prevent HIV outbreaks 
elsewhere in the region. Thus, CDC and Central Asia AIDS Project (CAAP), a regional 
entity, started to exchange ideas on how best to provide assistance to MoHs. 
CAAP and CDC already had a collaborative relationship. Working jointly, CAAP and 
CDC initiated HIV sentinel surveillance in Central Asian Republics of Kazakhstan, 
Kyrgyzstan, Tajikistan, and Uzbekistan. In addition to sentinel surveillance, CAAP and 
CDC also collaborated on laboratory issues in the region.  
 CDC/Central Asia Regional Office (CAR), based in Kazakhstan, has a long history 
of working in the region. It was initially established in 1997 and has been actively 
engaged in providing technical assistance to MoHs on HIV/AIDS since 2002. CAAP was 
established in 2005 through funding by World Bank and Department for International 
Development (DFID). Its main purpose is to control the spread of HIV/AIDS in the 
region by engaging stakeholders in the region and by building capacity of local NGOs. 
Since prevention of nosocomial infection was an area of overlap between CDC and 
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CAAP and because of a history of collaborative efforts between the two entities, both 
entities decided to collaborate in area of injection safety as well.  
During the discussions between two entities, it was agreed that the Central Asian 
countries needed a strategic plan to prevent nosocomial infection. However, the strategy 
and implementation plan would be based on country specific needs and in order to better 
understand the conditions in individual countries, it was agreed that additional data was 
needed.  
The first attempt to compile data was using MoHs resources, however, MoHs in 
the region have a very weak monitoring and evaluating system. Consequently, the type of 
data that was needed did not exist in most of the countries. It was then decided that there 
were only two options to gather the necessary data – 1) to conduct rapid assessment in 
select sites of each of the country or 2) to conduct national baseline assessment.  
During discussions with several other stakeholders, a concern was noted that by 
limiting data collection to a specific region of a given country, it may not accurately 
represent a national picture. Most of the countries in the region are diverse – their 
economic development, infrastructure, and other social phenomenon all vary 
considerably. Another concern which was noted that by limiting any assessment to a 
specific geographic area, CAAP and CDC may expose healthcare facilities and workers 
of those geographic area to national government scrutiny, which may jeopardize the 
intent of the assessment. Central Asia has a history of penalizing healthcare workers that 
may unintentionally expose patients to risks. Rather than dealing with the root of the 
problem, such as in-service/pre-service training of physicians, many countries have 
chosen to penalize their health care workers. One such example is Uzbekistan, where in 
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2010 a law was passed by the President holding healthcare workers criminally 
responsible for spreading HIV in medical facilities. Such laws have rarely resulted in 
reduction of  nosocomial infection, instead it generally results in resistance by physicians 
to diagnose patients with to avoid criminal penalties. Thus, to circumvent both of the 
issues, it was decided that data should be collected at the national level. Furthermore, it 
was decided that CAAP would provide the funding for the assessments, whereas, CDC 
will provide the technical expertise.  
The goal identified for the assessment was to collect baseline data in each country 
to assess the injection practices in hospitals and lower level health care facilities. It was 
agreed that the baseline assessment will be used to identify gaps in the healthcare system 
so recommendations could be made to host government on implementation of appropriate 
interventions.  
Consequently, CAAP and CDC followed-up with each of the Central Asian 
Republics, except Turkmenistan. Although no HIV outbreak had been reported in 
Turkmenistan, CAAP and CDC wanted to conduct national assessment in Turkmenistan 
as well. Officially, the government of Turkmenistan has reported only 2 HIV cases and 
does not acknowledge the existence of HIV in their country, which poses significant 
challenge in operating there. Despite documentation that other infectious diseases can be 
transmitted due to unsafe injection practices, the government of Turkmenistan gave no 
response, thus were excluded from this activity.   
The MoHs initially only agreed to hold conferences in each country to highlight 
and familiarize lead physicians and related public health workers to proper injecting 
techniques. After further communications with MoH, it was decided that the goal of the 
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conference will be to introduce international guidelines involving injection safety and 
related infection prevention and control practices (IPC). Consequently, in June 2009, two 
national conferences were conducted in Tajikistan and in Uzbekistan each, and by 
September 2009, another two conferences were conducted in Kyrgyzstan and Kazakhstan 
each. The conferences were attended by senior representatives of MoHs and included 
participants from each oblast (province) of each country. As a result of the conferences 
and discussions that took place during the conference, resolutions by the Ministry of 
Health were signed that granted CAAP and CDC approval to conduct national 
assessments with the goal to improve regulatory documents and national standards.   
As the first step towards developing an assessment tool, CDC/Central Asia 
Regional office (CDC/CAR) based in Almaty, Kazakhstan took the lead in developing a 
protocol and assessment tool for the national assessment in each country. CDC/CAR used 
the WHO developed injection safety assessment toolkit as a basis of structuring the 
assessment and adapted it to fit the needs of Central Asia. WHO had initially developed a 
tool for injection assessment in 2001 (Tool for the assessment of injection safety. 
Department of vaccines and biologicals. WHO, Geneva, 2001), but it was revised in 2007 
to include all vascular access points, such as intramuscular, subcutaneous and intradermal 
practice injections, phlebotomies, intravascular access devices, and procedures with a 
lancet (Tool for the assessment of Injection Safety and the Safety of Phlebotomy, Lancet 
Procedures, Intravenous Injections and Infusions. SIGN/WHO/Essential Health 
Technologies. 16 July, 2007).  
Drafts of protocol and assessment tool were shared with the MoHs at various 
intervals and many of their recommendations/suggestions were incorporated. Since the 
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lingua franca in the region is Russian, the protocol and all the questionnaires were written 
in English and translated into Russian when shared with the MoHs for their feedback. 
The Russian protocol and questionnaires were also translated back into English and 
compared to the original English transcribed protocol and questionnaires to verify 
accuracy of translation.  
The toolkit was also piloted at a few hospitals to gain feedback from target 
audients and participants. The pilot resulted in a few modifications of the questionnaires 
to accurately pose the question during the assessment. Once the final changes to the 
protocol and toolkit were made, they were submitted to MoHs for their final approval. 
MoH approval was received within a few week of the submission, after which it was 
submitted to CDC IRB for their approval. 
 Once IRB approval is received, CDC will hold a two-day training for data 
collectors/assessors in each of the country. Data collectors will be trained in a classroom 
setting with an introduction to Injection safety and waste management concepts.  This 
training will include a detailed review of the entire questionnaire including all 
instructions and steps.  Practice sessions will be held at a local hospital and lower level 
facility which are not included in the sample.  This will provide an opportunity to 
standardize the approach to data collection, to provide feedback on the performance of 
data collectors, and to field test the questionnaires in the local context.  In the first few 
days of the actual data collection, data collectors will receive close support from technical 
advisors and hired supervisors to ensure good quality data and to help address any issues 
that may arise. Data collectors are to be supervised throughout data collection by 
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supervisors; they will be provided with contact information to have immediate access to a 
supervisor as needed during data collection.  
The report will be written based on the results of the database analysis. It will be 
prepared by appropriate CDC staff, and will undergo technical review to ensure the 
overall quality of the report.  The report will follow the general outline provided to the 
analyst and will cover the different topics mentioned in the analysis plan.  
The final country-specific survey report will be shared with MoH. MoH will 
decide the sharing mechanism with other counterparts. Results may also be presented at 
conferences as lessons learned in the following areas (1) need for changing the behavior 
of health care workers to ensure safe injection practices through capacity building, 
behavior change and communications, and policy interventions; (2) ensuring the 
availability of safe injection equipment and supplies through procurement and logistics 
interventions; and (3) managing health care waste safely and appropriately; (4) 
reduction/elimination of unnecessary injections  
The results and the assessment will be presented as a report combined with 
information from other countries at a regional workshop for all countries of CAR.  This 
workshop will include national decision makers, the survey team, directors of large 
facilities where assessments were conducted and other national or international agencies 
with an interest in the results.  Results to be presented will be shown as aggregated results 
by CAR region, district or by type of facility (such as grouping all hospitals together, for 
example).  Data from individual countries will be presented only if there is preceding 
approval from the MoH of each country, and even then the name of the country will not 
be announced. If a country objects, then all data will be aggregated and shared. 
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It is hoped that once the data gained from the assessment will serve as advocacy 
tool that can be used to engage host governments in taking actions to prevent nosocomial 
infections in the region. The results of the assessment will also guide MoH, CAAP, CDC, 
and all stakeholders in developing a strategy that can be implemented in each country to 
avoid nosocomial infections in the region.    
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DISCLAIMER 
This procotol was submitted to CDC for review and approval by IRB, however, at 
the time of submission to GSU, the protocol had not been approved by CDC. 
Conssequently, the procol may undergo further changes before the assessment 
can  start. 
14 
 
ABBREVIATION AND SYMBOLS USED 
 
AIDS – Acquired Immunodeficiency Syndrome  
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1. INTRODUCTION  
 
1.1. Literature review 
Injections are one of the most common health care procedures. According to 
WHO data, there are 16 billion medical injections performed annually in 
developing and transitional countries. In countries where unnecessary injections 
are common, the average number of health care injections per person has been 
estimated to be 3.7 per year (Hauri AM et al., 2003). Half of them are unsafe 
injections (see definition, below).   The vast majority of injections, about 95%, are 
given in curative care 
(http://www.who.int/injection_safety/toolbox/en/InjectionFactSheet2002.pdf).  
 
WHO definition of safe medical procedures involving injections or other 
parenteral procedures:  A safe injection, phlebotomy, lancet procedure or intravenous device 
insertion does not harm 
the recipient, does not expose the provider to any avoidable risk and does not result in any waste 
that is dangerous for other people.” 
(http://www.who.int/injection_safety/Injection_safety_final-web.pdf).  
 
The term “injection safety” was initially used when it was recognized that 
injections—which are typically thought of as being intramuscular—may be an 
important mode of transmission of HIV or hepatitis viruses.  More recently, the 
term has been broadened to include other means of parenteral injection of 
substances (intravenously), withdrawing of blood (phlebotomy) or for 
intravenous/intra-arterial access (catheters in veins or arteries).  Thus, although 
the term used in this protocol is “injection safety,” the safety of additional medical 
procedures involving intravascular injection/access will be studied.   Injection 
safety includes practices intended to prevent transmission of infectious diseases 
between one patient and another, or between a patient and healthcare provider, 
and also to prevent harms such as needle stick injuries (Joseph F. Perz et al., 
2010).  
 
Injection safety is an important problem around the world. While there is 
disagreement among experts over the precise contribution of unsafe injection 
practices to global incidence of selected infections, each year, reuse or unsafe 
practice of injection devices may cause 20 million infections with hepatitis B virus 
(HBV), 2 million infections with hepatitis C virus (HCV), and 250 000 infections 
with human immunodeficiency virus (HIV) worldwide, accounting for 30%, 41% 
and 5% of new infections in 2000, respectively (Hauri AM et al., 2003). The 
probability of transmission of HBV via blood traces on syringes/needles may be 
as much as 20-40% in Health Care Facilities (HCF); on average, 6% of needle-
stick injuries involving HCV-infected patients has led to infection; and 
seroconversion risk following HIV-contaminated  needle-stick accidents has been 
estimated as 0.3% (L. Simonsen A. et al., 1999).  Also, improperly handled 
injectable medications   such as multi-dose vials may transmit blood borne 
pathogens (WHO/BCT/DCT 01.02); and the use of multi-dose vials has been 
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reported to be a potential source of infections in 19 studies (L. Simonsen A. et 
al., 1999).    
 
Environmental contamination within the HCF is a potential source of infection.  
For instance, HBV persists for up to seven days on surfaces (CDC. 
Recommendations for preventing transmission of infection among chronic 
hemodialysis patients. MMWR, 2001). In Romania, a review of injection practices 
revealed that HBV transmission was probably related to the preparation of 
injections in contaminated environments (Sautter RL et al., 1984).  
 
There are multiple poor injection practices which could lead to infections. An 
example is swabbing of vial tops or ampoules with an antiseptic or disinfectant 
when the disinfecting substances have been stored inappropriately (Nakashima 
AK et al., 1987; Reiss I et al., 2000). Needle-stick injuries to healthcare workers 
when administering injections are usually attributable to the brusque movements 
of patients (Jagger J et al., 1998; Haiduven DJ et al., 1992), and ensuring little 
movement of the patient or limb is partially preventable. A high proportion of 
needle-stick injuries are due to the two-handed recapping technique (Jagger et 
al., 1998), a very preventable practice, and unsafe sharps waste collection 
causes between 5% and 28% of needle-stick injuries (Khuri-Bulos NA et al., 
1997).   
 
A major concern that places both patient and HCW at risk is unnecessary 
injections. Two studies from the United Republic of Tanzania, one of which was a 
survey of 66 clinics, concluded that 70% of all curative injections given were 
unnecessary (Gumodoka B et al., 1996). An Indonesian survey calculated that 
82% of curative injections were unnecessary (Hogeboom van Buggenum et al., 
1993). In India, a study founded that 96% of all injections given by private doctors 
were for antibiotics, vitamins and analgesics (Greenhalgh T. et al., 1987). Two 
studies in Moscow, Russia concluded that 85% and 99% of injections given to 
hospitalized children were unnecessary (Loukina TN et al., 1993; Stekolschikova 
IA et al., 1993).  
 
Unsafe injections and vascular access practices are a notable problem for all 
CAR countries.   All findings mentioned above suggest that unsafe medical 
practices remain a significant health threat in Central Asia today. Among them 
are unnecessary injections, overuse of transfusions of blood and blood products, 
reuse of single use medical equipment, inadequate sterilization, improper 
disposal of sharps (e.g., needles, scalpel blades, etc.).  An example of a 
documented nosocomial HBV and HCV transmission in the region is a CDC/CAR 
study of HBV and HCV infection in a TB dispensary in 2002 which found that 
10% of HBV susceptible persons seroconvert within three months of beginning 
treatment at the dispensary. The seroconversion rate for HCV was similar. 
  
Nosocomial HIV infection cases have been reported from all countries of the 
region. One example is the HIV outbreak among children reported in South 
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Kazakhstan oblast (oblasts are the equivalent of States in America) in May 2006. 
An epidemiological investigation conducted by CDC/CAR found that the main risk 
factors for HIV infection among children during the outbreak were a history of 
blood transfusion and certain invasive procedures (subclavian line insertion). A 
similar HIV outbreak was reported in the southern part of Kyrgyzstan in 2007. 
Also Uzbekistan and Tajikistan have registered cases of nosocomial HIV 
infection. Unfortunately, there are no systematically-collected evidence-based 
data on injection practices in four of the CAR countries.   
 
WHO developed a tool for the assessment of injection safety in 2001 (Tool for 
the assessment of injection safety. Department of vaccines and biologicals. 
WHO, Geneva, 2001). Since then, this tool was used in over 90 national injection 
safety assessments; results were used to establish national standards for 
injection safety. A revised tool has been developed, which includes the 
assessment of intramuscular, subcutaneous and intradermal practice injections, 
also covers phlebotomies, intravascular access devices, and procedures with a 
lancet (Tool for the assessment of Injection Safety and the Safety of Phlebotomy, 
Lancet Procedures, Intravenous Injections and Infusions. SIGN/WHO/Essential 
Health Technologies. 16 July, 2007).  
 
MOH of have expressed concern about the contribution of hospital acquired 
(nosocomial) blood borne infections among registered HIV cases in children in 
three of the five Republics. At the present time, MOH of four countries have 
expressed the need and willingness to conduct an assessment of injection 
practices at the national level with the aim of receiving evidence-based data to 
then make decision with the goal of improving national standards and practices.  
 
Last year, CDC and CAAP discussed the best approach with which to provide 
technical assistance to each MOH and decided to conduct national conferences 
in four Central Asian countries. By June 2009, two national conferences were 
conducted, one in Tajikistan and one in Uzbekistan; by September 2009, another 
two conferences were conducted, in Kyrgyzstan and Kazakhstan. As a result of 
the conferences and discussions in working groups, resolutions by the Ministry of 
Health were signed. With the resolution, MOH of all four countries announced the 
need for national assessments of injection practices with the aim of using data 
from the assessments to improve regulatory documents and national standards 
(Prikazes). 
 
1.2. Justification for the assessment 
 
Recognizing from preliminary work that within CAR there is overuse of injections, 
unsafe practices, lack of single-use disposable injection equipment in some 
countries, and large problems with medical waste management, there is a need 
to conduct baseline assessments in at least four of the countries of CAR; a fifth 
has not given permission for such a survey. All countries mentioned above will 
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require a comprehensive approach toward using the data acquired and applying 
them to solving the problems likely to be encountered in the surveys.  
 
1.3. Intended/Potential use of the study 
 
The information collected during this study will provide baseline data on IS and 
waste management practices in countries of CAR (Kazakhstan, Kyrgyzstan, 
Uzbekistan and Tajikistan). The results of the baseline assessment will allow to 
MOHs to improve injection policies and establish an intervention strategy with the 
goal of reducing unnecessary injections and improving safe injection practices. A 
repeat assessment after implementation and completion of activities for 
improvement of injection practices is then anticipated; this study is statistically 
powered to allow such an assessment.  
 
2. OBJECTIVES  
 
2.1. Goal and general objectives of the assessment  
The goal is to conduct a baseline assessment of injection practices. The 
assessment will look for gaps in safe injection practices in hospitals and lower 
level HCFs. These identified gaps will be used for improvement of national 
policies in injection safety and healthcare waste management, and for the 
establishment of educational curricula for pre- and in-service trainings (the 
development of training to be also used as a capacity building exercise for MOH 
in how to train HCWs, including injection providers and waste handlers).   
 
The general objectives of the assessment include: 
 
1. Assessing the availability of injection equipment/materials.  
2. Describing the conditions and practices for administering injections and 
other related procedures. 
3. Assessing the availability of equipment/materials for the collection, 
transport and elimination of waste, as well as the procedures and 
practices relative to managing waste from injection and other injection-
related procedures and activities. 
4. Assessing the existence of reference documents (national policy, 
standards, and guidelines) in health facilities for injections and other 
injection related procedures. 
5. Assessing the number of accidental needle sticks among health care 
providers and waste handlers reported in the last 6 months. 
6. Assessing the barriers to reporting accidental needles sticks among health 
care providers.  
7. Assessing the knowledge of health care workers about infections 
transmitted through unsafe injections and accidental needle sticks. 
8. Assessing the vaccination status of the health care providers and waste 
handlers (hepatitis B).  
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2.2. Specific Objectives and Key Indicators 
 
The survey will seek to answer the following specific questions: 
• For each injection given, were the needle and syringe taken from a sterile 
pack?  
• For each phlebotomy, were the needle and syringe taken from a sterile 
pack or was a new phlebotomy set used? 
• For each catheter inserted, were the catheter and stylet taken from a 
sterile pack?   
• For cases where the needle and syringe were NOT taken from a sterile 
pack: Was there evidence that a used needle and/or syringe were being 
re-used on the same or a different patient without re-processing? 
• After the completion of the injection and other injection related procedure, 
was the used syringe/device recapped with two hands? 
• After each injection and other injection related procedure observed, did 
the provider immediately dispose of the used needles and syringes in an 
appropriate sharps container or use a needle remover?  
 
Key indicators to assess safe injection practices have been designed to reflect 
the goals of the study: 
• Key indicators to assess safe intramuscular injection practices  
• Use of new sterile devices for injections: “Proportion of intramuscular 
injections given with a new syringe and needle” 
•  Prevention of the  risk of needle stick injuries among providers by 
eliminating recapping: “proportion of intramuscular injections given by 
HCWs who dispose of used sharps involving needles without recapping 
them” 
• Prevention of the risk for needle stick injuries among HCWs: “Proportion 
of intramuscular injections given by HCWs who dispose of used sharps in 
a safety box or puncture-proof, leak-proof sharps container (or use a 
needle remover) immediately after injection/injection related procedure”  
• Key indicators to assess safe intravenous injection practices  
• Use of new sterile devices for injections: “Proportion of intravenous 
injections given with a new syringe and needle” 
•  Prevention of the  risk of needle stick injuries among providers by 
eliminating recapping: “proportion of intravenous injections given by 
HCWs who dispose of used sharps involving needles without recapping 
them” 
• Prevention of the risk for needle stick injuries among HCWs: “Proportion 
of intravenous injections given by HCWs who dispose of used sharps in a 
safety box or puncture-proof, leak-proof sharps container (or use a needle 
remover) immediately after injection/injection related procedure”  
• Key indicators to assess safe phlebotomy practices  
• Use of new sterile devices for phlebotomies: “Proportion of phlebotomies 
given with a new syringe and needle” 
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•  Prevention of the  risk of needle stick injuries among providers by 
eliminating recapping: “proportion of phlebotomies given by HCWs who 
dispose of used sharps involving needles without recapping them” 
• Prevention of the risk for needle stick injuries among HCWs: “Proportion 
of phlebotomies given by HCWs who dispose of used sharps in a safety 
box or puncture-proof, leak-proof sharps container (or use a needle 
remover) immediately after injection/injection related procedure”  
• Key indicators to assess safe IV procedures through CVC and PVC:   
• Use of new sterile devices for phlebotomies: “Proportion of phlebotomies 
given with a new syringe and needle” 
•  Prevention of the  risk of needle stick injuries among providers by 
eliminating recapping: “proportion of phlebotomies given by HCWs who 
dispose of used sharps involving needles without recapping them” 
• Prevention of the risk for needle stick injuries among HCWs: “Proportion 
of phlebotomies given by HCWs who dispose of used sharps in a safety 
box or puncture-proof, leak-proof sharps container (or use a needle 
remover) immediately after injection/injection related procedure”  
 
 3. EXPECTED TYPES OF RESULTS   
 
The results expected at the end of the baseline assessment are listed below: 
 
3.1. In the area of managing injection equipment and waste management 
products, data will be collected on: 
• The  length of time that injection commodities or equipment  or safety 
boxes are out of stock 
• The appropriate amount of injection equipment and safety boxes available 
in the inventory by type and by size  
 
3.2. In the area of injection administration, data will be collected on:  
• Packaging of the injection equipment (new and sterile package) 
• The reconstitution of medications/ vaccines 
• Cleaning or use of an antiseptic at the injection site prior to administration  
• The practice of ‘‘re-capping’’ needles after injection 
• The use of safety boxes to collect used injection equipment 
(syringes/needles) (see appendix 3, section 1, Q 1.07) 
• The use of needle removers on used injection equipment 
• Training on injection safety 
 
3.3. In the area of infection prevention and control, data will be collected 
on: 
• The hygienic conditions of injection preparation and administration (see 
appendix 3, Section 3, Q 3.1.)  
• The hand hygiene practice of HCWs administering the injection 
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• The number of accidental needle sticks among health care providers and 
waste handlers reported in the last 6 months 
• The knowledge of health care workers of infections transmitted through 
unsafe injections and accidental needle sticks 
• The vaccination status of the health care providers and waste handlers 
(hepatitis B) 
 
3.4. In the area of estimating needs relative to injection safety, data will be 
collected on: 
• The existence of reference documents on injection safety (national policy, 
standards and guidelines) 
• Forecasting adequacy-the regularity of the supply of products, injection 
equipment and waste management materials 
• The adequacy of the amounts on-site of injectable products, injection 
equipment, waste management material 
 
3.5. In the area of medical waste management, data will be collected on: 
• Medical waste-final disposal  methods 
• Method of eliminating ashes following incineration (if there is an 
incinerator) 
• Maintenance of the incinerator (if there is an incinerator) 
• Problems encountered relative to final medical waste disposal 
• Vaccination status of the health workers responsible for waste 
management (hepatitis B) 
• Type of protective equipment available and used 
• Training in medical waste management  
 
 
 4. MATERIALS AND METHODS  
 
4. 1. Type and Duration of the Survey  
 
All assessments are cross-sectional surveys.  The assessments in Kazakhstan 
and Kyrgyzstan are being performed with HCF’s that will be randomly selected, 
while the assessments in Tajikistan and Uzbekistan will be done in preselected 
HCFs (lists of HCFs are provided by MOHs). Data will be gathered via interviews 
with facility staff, facility-based observations, and review of stock and inventories 
of materials in the visited HCFs.  
 
The total duration of the assessment starting with training for assessors and 
finishing with the production of the final report is described in Appendix 1. 
 
4.2. Units of Analysis and Target Populations  
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The unit and target populations of the injection safety assessment include the 
following: 
 
• Survey Units 
The sample will be stratified by facility type to include the following (tailored as 
appropriate to the country work plan and expansion plan): 
• Oblast-level and city-level hospitals, and polyclinics   
• Adult hospitals: intensive care, theraputical, surgical, obstetrics, 
outpatient and laboratory 
• Pediatric hospitals: intensive care, theraputical, surgical, outpatient and 
laboratory  
• Rayon-level hospitals (no separate hospitals for adult and pediatric 
services) 
• Departments: intensive care, therapeutical, surgical, obstetrics, 
pediatric, outpatient and laboratory.    
• Public health centers, health posts in the rayon level villages (primary 
health care services).   
• Tertiary hospitals (specific for Uzbekistan, as provided by MoH).  
 
• Target Populations 
 
The target populations are selected staff and patients of the following types: 
• Staff administering injections and phlebotomy 
• Supervisors of the staff responsible for administering injections and 
phlebotomy  
• Staff in charge of medical waste management 
• Patients of observed departments/facilities  
 
4.3. Sample Size Calculations  
 
This is proposed study protocol for four countries of CAR and thus sample size 
calculations presented here are country-specific.  
 
Nevertheless, types of procedures and types of HCFs will be same for all 
countries (table 1). 
 
Table 1. Health care services included in assessment and types of 
procedures.  
 
Service Procedures 
Outpatient Services: 
All diagnostic, curative and preventive  
 
1. Injections – IM, IV 
2. IV infusions 
3. Phlebotomies  
Hospitals: 
Theraputical, surgical, obstetric-
gynecological, pediatric, laboratory, 
1. IM injections 
2. IV Injections 
3. IV infusions, including these 
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ICU, outpatient departments through CVC and PVC 
4. Phlebotomies  
LL HCFs: 
Both curative and vaccination 
 
1. IM/SC 
2. IV injections 
 
Kazakhstan and Kyrgyzstan 
 
The objective of the study, as stated above in Section 2, is to assess injection 
practices in hospitals as well as lower-level facilities in the country.  Statistical 
testing is planned for the comparisons of data acquired from the baseline 
assessment, listed in Section 4.4.   
 
The sampling unit is the HCF. Two-stage, cluster-sampling self method through 
choice in which clusters are selected using probability proportional to population 
size and equal numbers of sampling units within each cluster. As clusters, rayons 
and cities were selected.  There are a finite number of HCFs in the clusters 
covered by this survey. Ten HCFs per cluster were selected, including 2 oblast 
level HCFs to which rayon belongs.  We are going to observe four types of 
injections and related procedures:  phlebotomies, IV and IM injections, IV 
infusions, including these through CVC and PVC.  We assume a design effect of 
2.0, beta of 0.80 and alpha of 0.05 and calculated the sample sizes as described 
below using the Power and Sample Size (PASS) software package 
 
For the four types of procedures, we assume (in the absence of data) that 15% of 
each procedure is unsafe. We assume that our intervention will decrease the 
proportion of unsafe procedures to 5% after intervention. We calculate a sample 
size of 320 observations for each procedure. We estimate that two injections (2 
curative and 2 immunization) will be observed in each lower-level facility and 
eight  procedures 2 IM, 2 IV, 2 phlebotomies,  2 IV infusions, including these 
through CVC and PVC, in each of up to seven (7) departments of each of the 
selected hospitals.  These injection observations will be used to evaluate key 
indicators (table 2a and 2b).  
 
In terms of CVCs, we assume (in the absence of data) that 30% of them are 
unsafe during baseline assessment.  We assume that our intervention—if it is to 
have a “significant” impact on the proportion of unsafe practices--will decrease 
the proportion of unsafe CVCs to 5% after intervention.  We calculate a sample 
size of observations for catheterizations of 78 per country. Although we are 
interested in CVCs, we believe it will difficult to observe enough number of 
procedures, uncertainty about number and timing of CVC insertion at the 
facilities, and the length of time (minimum, 25 minutes) required to observe a 
complete CVC procedure.  We will prioritize CVC observation in our visits and 
learn what we can, although we are uncertain we can achieve the hoped-for 
number of 78 observations. 
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The allocated number of injection observations for each of the four procedures by 
rayon will, unlike for CVC, far exceed the calculated sample size.  Given this, 
injection practices may be analyzed and then presented by higher-level facility 
(hospital) and lower-level facilities (medical post), provided there are enough 
cases in each for this level of analysis but such a comparison is not a primary 
intent of our study.  
  
Uzbekistan and Tajikistan 
 
As it was mentioned above, the MOHs of both countries chose not to use random 
sampling and, instead, provided CAAP and CDC with preselected list of HCFs.   
We believe that the assessment of practices using the lists provided by MOHs 
will provide valuable information.   
 
The sampling unit is the HCF.  These HCFs include oblast hospitals, rayon 
hospitals, city level hospitals/District hospitals (which are lower-level hospitals) 
and outpatient clinics or LL HCFs (Medical posts) as well. For Uzbekistan, MOH 
also selected tertiary hospitals.  
 
For Uzbekistan, in which we used 75 HCFs given to us by the country, we have 
no good way of knowing how representative they are of all HCFs. But, every 
oblast is represented in the sample with at least one HCF and a range of types of 
HCFs is included, i.e., oblast level, rayon-level and lower level.  
 
For Tajikistan, in which we used sample of 106 HCFs given to us, all oblast- and 
rayon-level hospitals were included, as were a variety of lower-level facilities. To 
attempt to obtain a representative “picture” of practices, a sample will be drawn 
from across the study area. It is estimated that four injections (2 curative and 2 
immunization) will be observed in each lower-level facility and six (2 IM, 2 IV and 
2 phlebotomies) in each one of up to seven (7) departments of each of the 
selected hospitals.  These injection observations will be used to evaluate key 
indicators (table 2c and 2d).  
 
4.4. Sampling Techniques in Health Districts and Health Facilities  
 
Kazakhstan and Kyrgyzstan  
 
The sampling of health facilities assessed will be obtained through a combination 
of purposeful and random selection. In each cluster to be assessed, the following 
approach will be used:  
• Oblasts are listed haphazardly (using a listing provided by Ministry, which 
was not alphabetical and Ministry did not know the intent of use of the list) 
with all their rayons.  .   
• The initial rayon is to be selected by random number from the listing of 
oblast/rayons.  This rayon belongs to an oblast and defines the oblast that 
will be included in the study.  
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• Purposeful selection will be used for selecting oblast hospitals, rayon 
hospitals, and lower-level hospitals (so that oblast level, rayon level, and 
lower-level hospitals are included).  There are 1-2 oblast hospitals, 1 
(occasionally 2) rayon-level hospitals, and generally lower-level hospitals.  
All will be included, because it is in hospitals that injections or catheters 
are used.  Selecting lower-level primary HCFs (see next bullet) runs the 
risk of identifying a HCF but in which there may be no procedures being 
done the day of the visit.  
• Random sampling will then be used for selecting lower-level primary 
HCFs, using a computer-generated random number selection.  Nine is 
generally considered to be a reasonable number of facilities in an 
assessment of this type and we shall select 10.  Each unit of analysis 
should have this number of facilities at a minimum.   
• The second rayon is then selected by PPS and the above process 
repeats.  The sampling interval was the entire population of the country 
divided by 8.  We applied the sampling interval to the cumulative 
population in the Excel sheet (as described in the first bullet) to select the 
next rayon.  We then repeated the process just described.  Our goal was 
to get 80 HCFs, and to always have the oblast-level, rayon-level, and 
lower-level hospitals and, then, primary care HCFs. 
• Attached (Appendix 8 KZ sampling.doc and Appendix 9 KG sampling.xls) 
are files that contain the sampling schemes. 
 
Observations or syringe use for injections and phlebotomy will be conducted in 
the hospital service areas where the majority of syringes and needles are used. 
In Central Asia health care facilities perform procedures such as phlebotomy, 
injection and catheter insertion in special areas.  These include: ICU, medical 
department, pediatrics, gynecology-obstetrics, outpatient care, the phlebotomy 
area of the laboratory, and surgical ward1, as well as stock room of each 
department. It is important to note that not all hospitals will have all seven 
departments.  The survey will include all of the areas listed above that exist at 
each facility.2   
 
The assessment will be carried out in the health districts and numbers of facilities 
in Kazakhstan and Kyrgyzstan is shown in Table 1a and b. 
 
                                                 
1
 Surgical department is listed as an area but it should be noted that this refers to pre-operative 
procedures and post-operative procedures.  Data collectors will not attempt to observe actual 
surgeries.  
2 The specific types of service departments may vary by hospital.  The goal is to include all areas 
with high numbers of injections or use of injection equipment as well as the stock room.  While it 
is recognized that there may be other locations where injections can occasionally be observed, it 
is not necessary to visit those areas for this quantitative data collection.  However, those areas 
can and should be visited during supervisory visits.  Dental clinics are not a suggested location 
for data collection because there are usually too few of them for quantitative analysis. Trauma 
centers and psychiatric departments are not recommended sites of data collection because the 
data collectors risk interfering with patient treatment. 
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Uzbekistan and Tajikistan  
 
Assessment will be done in preselected HCFs. Observations of needle/syringe 
use for injections and phlebotomy will be conducted in the seven departments 
where the majority of syringes and needles are used. These include: ICU, 
medical department, pediatrics, gynecology-obstetrics, outpatient care, the 
phlebotomy area of the laboratory, and surgical, as well as stock room of each 
department. It is important to note that not all hospitals will have all seven 
departments.  The survey will include all of the areas listed above that exist at 
each facility.   
  
Table 1a: Health Districts and Facilities in Kazakhstan to be Covered 
by This Survey 
Districts  # Oblast 
hospital
s*  
# 
Rayon 
hospita
ls 
# 
District 
hospita
ls 
# LL 
HCF
s 
# City 
hospita
ls 
# 
Outpatie
nt clinics 
Tota
l # 
of 
HCF
s 
 Ulansky 
rayon (East 
Kazakhsta
n Oblast) 
1 1 2 6 0 0 10 
Shetsky 
rayon 
(Karagand
a) 
2 2 0 6 0 0 10 
Ekibaztuz 
city 
(Pavlodar 
oblast) 
2 0 1 3 1 3 10 
Astrakhans
ky rayon 
(Akmola 
Oblast) 
2 1 1 5 0 1 10 
Makhtarals
ky rayon 
(SKO) 
1 4 0 0 0 5 10 
Shymkent 
city (SKO) 
1 0 0 2 5 2 10 
Kurmangaz
y rayon 
(Atyrau 
oblast) 
2 1 4 3 0 0 10 
Almaty  0 0 0 0 5 5 10 
Total 11 9 8 25 11 16 80 
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* For each oblast it can have 1 or 2 oblast hospitals; no oblast has more 
than 2 hospitals.  
 
Table 1b: Health Districts and Facilities in Kyrgyzstan to be Covered 
by This Survey 
 
Districts  # Oblast 
hospital
s*  
# 
Rayon 
hospita
ls 
# 
District 
hospita
ls 
# LL 
HCF
s 
# City 
hospita
ls 
# 
Outpatie
nt 
clinics 
Tota
l # 
of 
HCF
s 
Sokoluk 
(Chu oblast) 
1 1 2 5 0 1 10 
Batken 
(Kadamjay) 
2 2 5 0 0 2 11 
Talas 
(Karabura) 
1 1 0 6 0 2 10 
Aravan 
(Osh) 
2 3 0 4 0 1 10 
Nookat 
(Osh) 
0 8 0 0 0 2 10 
Jalalabat 
(Bazarkurga
n) 
1 1 0 7 0 1 10 
Issyk-Kul 1 0 0 4 2 2 9 
Bishkek 0 0 0 0 3 7 10 
Total 8 16 7 26 5 18 80 
* For each oblast it can have 1 or 2 oblast hospitals; no oblast has more 
than 2 hospitals.  
 
 
The lists of HCFs for Kazakhstan, Kyrgyzstan, Uzbekistan and Tajikistan 
are presented in Appendix 2.  
 
4.5.   Study Populations / Areas 
 
A description of data to be collected from each study population/area can be 
found below. Details for can be found in Table 3 at the end of this section.  
 
4.5.1 Inventory / Stock Rooms  
 
Each stock room of each department of each hospital (7 departments will 
be under observation or, if fewer than 7 departments exist, as many as do 
exist) and each procedure site within each department hand stock will be 
assessed.  In LLHCFs, 1 stock room will be assessed. In total, 7 stock 
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rooms per hospital (or, if fewer, if there are fewer than 7 departments) and 
1 stock room per LLF will be assessed.  
 
4.5.2 Observation of departments and entire HCFs  
 
The observations are conducted in and around the facility and compiled 
onto 1 questionnaire. Observations outside the facility are limited to the 
facility grounds. A total of 1 set of observations covering the entire hospital 
and 1 set of observations per lower-level facility will be completed.   These 
observations will be analyzed by department with a total of 7 sets of 
observations per hospital and 1 per lower-level facility in each country. 
 
Thus, 7 departments or fewer will be observed per hospital. One 
department of each type (general, ICU, surgical, obstetric, pediatric, 
laboratory and outpatient) well be assessed. If, however, a hospital has 3 
departments of one type, only one department will be chosen randomly for 
assessment. If there are more than two departments of one type, the 
number of these departments will be placed into “a hat” and randomly 
draw one from the hat; if there are two, assessors will flip a coin.  
 
4.5.3 Injections Observed 
 
The observations are conducted where the injections are given (patient 
bedside, injection room, etc).  Usually, these services are concentrated in 
one or two rooms in lower level facilities.  Data will be collected in both 
inpatient and outpatient settings.  In hospitals, observations will be 
conducted in the departments listed in Section 4.4.   If more than one 
HCW is providing procedures during observations, all HCWs will be 
observed. Although four injection observations are planned for each lower-
level facility and eight injection observations per each department of each 
hospital, there will be fewer observations if not all hospitals have all 7 
departments or if some lower-level facilities or hospital departments have 
fewer than 4 injections taking place during the time of the data collection 
visit.   
 
 
Kazakhstan  
 
A sampling of injections observed will be devised in the following manner: 
 
• Hospitals: 8 injections and related procedures per service 
area (department), that is, 8 in medicine, 8 in  pediatrics, 8 in 
gynecology-obstetrics, 8 in surgical , 8 in the laboratory, 8 in ICU 
and 8 in the outpatient department  (8 injections per service area 
x 7 departments x 39 hospitals). Total: 2,184 injections will be 
observed.    
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• City outpatient clinics:  8 injections per service area 
(department), that is, 8 in laboratory and 8 injections where 
patients receive treatment (8 injections per service area x 2 
service areas x 16 HCFs). Total 256 injections will be observed.  
 
• Lower-level health facilities: 4 injections per facility of which 
2 should be a vaccination, 2 curative3. Note that the goal is to 
observe 4 injections. Data collectors should observe no more 
than 2 immunizations and 2 curative injections. (4 injections per 
facility x 25 HCFs). Total: 100 injections will be observed (see 
Table 2).  
 
 
Table 2a: Total number of procedures to be observed in HCFs, 
Kazakhstan.  
 
HCFs # of 
HCFs 
# of 
departments 
# of 
procedures 
per 
department  
 Total # of 
procedures  
Hospitals  39 7 8 2184 
City outpatient clinics 16 2 8 256 
Lower level HCFs 25 1 4 100 
Total  80   2540 
 
Kyrgyzstan 
 
A sampling of injections observed will be devised in the following manner: 
 
• Hospitals: 8 injections per service area (department), that is, 
8 in medicine, 8 in  pediatrics, 8 in gynecology-obstetrics, 8 in 
surgical , 8 in the laboratory, 8 in ICU and 8 in the outpatient 
department  (8 injections per service area x 7 service areas x 36 
hospitals). Total 2016 injections will be observed.    
 
• City outpatient clinics:  8 injections per service area 
(department), that is, 8 in laboratory and 8 in s where patients 
receive treatment (8 injections per service area x 2 service 
areas x 18 HCFs). Total 288 injections will be observed.  
 
• Lower-level health facilities: 4 injections per facility of which 
2 should be a vaccination, 2 curative. Note that the goal is to 
                                                 
3
 The purpose of this is to have a sample of each type of HCF and practices for analysis.  This way will 
allow us to have national wide data. 
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observe 4 injections. Data collectors should observe no more 
than 2 immunizations and 2 curative injections. (4 injections per 
facility x 26 HCFs). Total 104 injections will be observed (see 
Table 2b).  
 
Table 2b: Total number of procedures to be observed in HCFs, 
Kyrgyzstan.  
 
HCFs # of 
HCFs 
# of 
departments 
# of 
procedures 
per 
department  
 Total # of 
procedures  
Hospitals  36 7 8 2016 
City outpatient clinics 18 2 8 288 
Lower level HCFs 26 1 4 104 
Total  80   2408 
 
Uzbekistan  
 
A sampling of injections observed will be devised in the following manner: 
 
• Hospitals: 8 injections per service area (department), that is, 
8 in medicine, 8 in  pediatrics, 8 in gynecology-obstetrics, 8 in 
surgical , 8 in the laboratory, 8 in ICU and 8 in the outpatient 
department  (8 injections per service area x 7 service areas x 65 
hospitals). Total 3640 injections will be observed.    
 
• City outpatient clinics:  8 injections per service area 
(department), that is, 6 in laboratory and 6 in s where patients 
receive treatment (8 injections per service area x 2 service 
areas x 4HCFs). Total 64 injections will be observed.  
 
• Lower-level health facilities: 4 injections per facility of which 
2 should be a vaccination, 2 curative. Note that the goal is to 
observe 4 injections. Data collectors should observe no more 
than 2 immunizations and 2 curative injections. (4 injections per 
facility x 6 HCFs). Total 24 injections will be observed (see 
Table 2c).  
 
Table 2c: Total number of procedures to be observed in HCFs, 
Uzbekistan.  
 
HCFs # of 
HCFs 
# of 
departments 
# of 
procedures 
per 
department  
 Total # of 
procedures  
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Hospitals  65 7 8 3640 
City outpatient clinics 4 2 8 64 
Lower level HCFs 6 1 4 24 
Total  75   3728 
 
Tajikistan  
 
A sampling of injections observed will be devised in the following manner: 
 
• Hospitals: 8 injections per service area (department), that is, 
8 in medicine, 8 in  pediatrics, 8 in gynecology-obstetrics, 8 in 
surgical , 8 in the laboratory, 8 in ICU and 8 in the outpatient 
department  (8 injections per service area x 7 service areas x 28 
hospitals). Total 1624 injections will be observed.    
 
• City outpatient clinics:  8 injections per service area 
(department), that is, 8 in laboratory and 8 in s where patients 
receive treatment (8 injections per service area x 8 service 
areas x 25HCFs). Total 400 injections will be observed.  
 
• Lower-level health facilities: 4 injections per facility of which 
2 should be a vaccination, 2 curative. Note that the goal is to 
observe 4 injections. Data collectors should observe no more 
than 2 immunizations and 2 curative injections. (4 injections per 
facility x 53 HCFs). Total 212 injections will be observed (see 
Table 2d).  
 
Table 2d: Total number of procedures to be observed in HCFs, 
Tajikistan.  
 
HCFs # of 
HCFs 
# of 
departments 
# of 
procedures 
per 
department  
 Total # of 
procedures  
Hospitals  29 7 8 1624 
City outpatient clinics 25 2 8 400 
Lower level HCFs 53 1 4 212 
Total  106   2236 
 
 
4.5.4 Injection Administrators 
 
A single person (“injection administrator”) performing injections within each 
department will be chosen for the injection provider interview. This is a 
quota/convenience sample of one.  The injection administrator to be 
interviewed will be the health worker who administers the largest number 
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of injections being observed on the day of data collection in each facility 
(or, in the case of the laboratories, the one who uses the largest numbers 
of devices to draw blood). Usually, this will be the treatment room nurse in 
each department or the laboratory technician responsible for blood 
drawing. 
 
Kazakhstan:  
 
Injection providers will be sampled according to the following 
breakdown: 
 
• Hospitals: 1 participant per service area: 1 in the medical 
department, 1 in pediatrics, 1 in gynecology-obstetrics, 1 in surgical , 1 
in ICU , 1 in the laboratory, and 1 in the outpatient department.  (7 
participants x 39hospitals). Total 273 participants.  
 
• City outpatient clinics: 1 participant per service area: 1 in the 
laboratory and 1 in  for treatment. (2 participants x 16 HCFs). Total 32 
participants.  
 
• Lower-level facilities4: 1 participant per facility (1 participant x 25 
facilities). Total 25 participants.  
 
Kyrgyzstan:  
 
Injection providers will be sampled according to the following 
breakdown: 
 
• Hospitals: 1 participant per service area: 1 in the medical 
department, 1 in pediatrics, 1 in gynecology-obstetrics, 1 in surgical , 1 
in ICU , 1 in the laboratory, and 1 in the outpatient department.  (7 
participants x 36 hospitals). Total 252 participants.  
 
• City outpatient clinics: 1 participant per service area: 1 in the 
laboratory and 1 in  department for treatment. (2 participants x 18 
HCFs). Total 36 participants.  
 
 
• Lower-level facilities: 1 participant per facility (1 participant x 26 
facilities). Total 26 participants.  
                                                 
4
 If the configuration of a lower-level facility is such that there are essentially two separate departments, 
each with its own staff, then it may be possible to take 1 participant from each department. For example, if 
there are urban health centers, each of which has an outpatient area and a maternity area with its own staff, 
it would be possible to select 1 participant in the outpatient area and 1 in the maternity department. This 
approach would double the number of participants in the facility, as currently only one participant per 
facility is planned.   
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Uzbekistan  
 
Injection providers will be sampled according to the following 
breakdown: 
 
• Hospitals: 1 participant per service area: 1 in the medical 
department, 1 in pediatrics, 1 in gynecology-obstetrics, 1 in surgical 
department, 1 in ICU , 1 in the laboratory, and 1 in the outpatient 
department.  (7 participants x 65 hospitals). Total 455 participants.  
 
• City outpatient clinics: 1 participant per service area: 1 in the 
laboratory and 1 in department   for treatment. (2 participants x 4 HCFs). 
Total 8 participants.  
 
 
• Lower-level facilities: 1 participant per facility (1 participant x 6 
facilities). Total 6 participants.  
 
 
Tajikistan  
 
Injection providers will be sampled according to the following 
breakdown: 
 
• Hospitals: 1 participant per service area: 1 in the medical 
department, 1 in pediatrics, 1 in gynecology-obstetrics, 1 in surgical 
department, 1 in ICU , 1 in the laboratory, and 1 in the outpatient 
department.  (7 participants x 28 hospitals). Total 196 participants.  
 
• City outpatient clinics: 1 participant per service area: 1 in the 
laboratory and 1 in department for treatment. (2 participants x 25 HCFs). 
Total 50 participants.  
 
 
• Lower-level facilities: 1 participant per facility (1 participant x 53 
facilities). Total 53 participants.  
 
 
4.5.5 Supervisors of injection providers 
 
Kazakhstan  
 
Supervisors of the staff responsible for administering injections or blood 
draws will be selected according to the following breakdown: 
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• Hospitals: 1 participant per service area: 1 supervisor in the medical 
department, 1 in pediatrics, 1 gynecology-obstetrics, 1 in surgical 
department, 1 in ICU, 1 in the laboratory, and 1 in the outpatient 
department    (7 participants x 39 hospitals). Total 273 participants.  
  
• City outpatient clinics: 1 participant per service area:  1 supervisor 
in the laboratory and 1 in department where treatment is provided. (2 
participants x 16 HCFs). Total 32 participants 
 
• Lower-level facilities: 1 participant per facility (1 participant x 25 
facilities). Total 25 participants.  
 
Kyrgyzstan  
 
Supervisors of the staff responsible for administering injections or blood 
draws will be selected according to the following breakdown: 
 
• Hospitals: 1 participant per service area: 1 supervisor in the medical 
department, 1 in pediatrics, 1 gynecology-obstetrics, 1 in surgical ,  1 in 
ICU, 1 in the laboratory, and 1 in the outpatient department    (7 
participants x 36 hospitals). Total 252participants.  
  
• City outpatient clinics: 1 participant per service area:  1 supervisor 
in the laboratory and 1 in department where treatment is provided. (2 
participants x 18 HCFs). Total 36 participants 
 
• Lower-level facilities: 1 participant per facility (1 participant x 26 
facilities). Total 26 participants.  
 
 
Uzbekistan  
 
Supervisors of the staff responsible for administering injections or blood 
draws will be selected according to the following breakdown: 
 
• Hospitals: 1 participant per service area: 1 supervisor in the medical 
department, 1 in pediatrics, 1 gynecology-obstetrics, 1 in surgical 
department,  1 in ICU, 1 in the laboratory, and 1 in the outpatient 
department    (7 participants x 65 hospitals). Total 455 participants.  
  
• City outpatient clinics: 1 participant per service area:  1 supervisor 
in the laboratory and 1 in department, where treatment is provided. (2 
participants x 4 HCFs). Total 8 participants 
 
• Lower-level facilities: 1 participant per facility (1 participant x 6 
facilities). Total 6 participants.  
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Tajikistan   
 
Supervisors of the staff responsible for administering injections or blood 
draws will be selected according to the following breakdown: 
 
• Hospitals: 1 participant per service area: 1 supervisor in the medical 
department, 1 in pediatrics, 1 gynecology-obstetrics, 1 in surgical 
department,  1 in ICU, 1 in the laboratory, and 1 in the outpatient 
department    (7 participants x 28 hospitals). Total 196 participants.  
  
• City outpatient clinics: 1 participant per service area:  1 supervisor 
in the laboratory and 1 in department, where treatment is provided. (2 
participants x 25 HCFs). Total 50 participants 
 
• Lower-level facilities: 1 participant per facility (1 participant x 53 
facilities). Total 53 participants.  
 
4.5.6 Staff in charge of waste management 
  
Kazakhstan and Kyrgyzstan  
 
Among staff responsible for waste management, only the main person 
responsible for waste management will be interviewed. So, 1 participant 
per hospital and 1 participant per lower-level facility will be selected 
for interview. Total: 80 participants per country will be selected for 
interview.  
 
Uzbekistan and Tajikistan  
 
Among staff responsible for waste management, only main person 
responsible for waste management will be interviewed. So, 1 participant 
per hospital and 1 participant per lower-level facility will be selected 
for interview. Total: 75 participants in Uzbekistan and 106 participants in 
Tajikistan will be interviewed.   
 
4.5.7 Patients, hospitalized in the observed departments  
  
Kazakhstan  
 
Patients receiving medical care in these healthcare facilities will be 
selected for interview according following breakdown.   
• Hospitals: 4 participants per service area: 4 patients in the medical 
department, 4 parents in pediatrics, 4 patients in gynecology-
obstetrics, 4 patients in surgical, 4 patients in outpatient department, 4 
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patients in laboratory, excluding ICU (4 participants x 6 departments x 
36 hospitals). Total 864 participants.  
  
• City outpatient clinics: 4 participants per service area:  4 patients 
in the laboratory and 4 in department, where treatment is provided. (8 
participants x 16 HCFs). Total 128 participants 
 
• Lower-level facilities: 2 participants per facility (2 participant x 25 
facilities). Total 50 participants.  
 
Kyrgyzstan   
 
Patients receiving medical care in these healthcare facilities will be 
selected for interview according following breakdown.   
• Hospitals: 4 participants per service area: 4 patients in the medical 
department, 4 parents in pediatrics, 4 patients in gynecology-
obstetrics, 4 patients in surgical department, 4 patients in outpatient 
department and 4 patients in laboratory, excluding ICU (4 participants x 
6 departments x 36 hospitals). Total 864 participants.  
  
• City outpatient clinics: 4 participants per service area:  4 patients 
in the laboratory and 4 in department, where treatment is provided. (8 
participants x 18 HCFs). Total 144 participants 
 
• Lower-level facilities: 2 participants per facility (2 participant x 25 
facilities). Total 52 participants.  
 
Uzbekistan   
 
Patients receiving medical care in these healthcare facilities will be 
selected for interview according following breakdown.   
• Hospitals: 4 participants per service area: 4 patients in the medical 
department, 4 parents in pediatrics, 4 gynecology-obstetrics, 4 in 
surgical department, 4 patients in outpatient department and 4 patients 
in laboratory, excluding ICU (4 participants x 6departments x 65 
hospitals). Total 1560 participants.  
  
• City outpatient clinics: 4 participants per service area:  4 patients 
in the laboratory and 4 in department, where treatment is provided. (8 
participants x 4 HCFs). Total 32 participants 
 
• Lower-level facilities: 2 participants per facility (2 participant x 6 
facilities). Total 12 participants.  
Tajikistan   
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Patients receiving medical care in these healthcare facilities will be 
selected for interview according following breakdown.   
• Hospitals: 4 participants per service area: 4 patients in the medical 
department, 4 parents in pediatrics, 4 patients in gynecology-
obstetrics, 4 patients in surgical department, 4 patients in outpatient 
department and 4 patients in laboratory, excluding ICU (4 participants x 
6 departments x 28 hospitals). Total 672 participants.  
  
• City outpatient clinics: 4 participants per service area:  4 patients 
in the laboratory and 4 in department, where treatment is provided. (8 
participants x 25 HCFs). Total 200 participants 
 
• Lower-level facilities: 2 participants per facility (2 participant x 53 
facilities). Total 106 participants.  
 
Table 3a: Target Population Sample for Kazakhstan  
 
 
 # Target Population 
Sample size 
Hospitals  City 
outpatient 
LL HCFs Total 
1 Stock room inventory 273 32 25 329 
2 HCF observations 39 16 25 80 
3 Observations of injections or phlebotomy  2184 256 100 2540 
4 Injection administrator interviews  273 32 25 330 
5 Interviews with supervisors of injection 
administrators 
273 32 25 330 
6 Waste management interviews 39 16 25 80 
7 Patients 864 128 50 1042 
 
Table 3b: Target Population Sample for Kyrgyzstan  
 
 
 # Target Population 
Sample size 
Hospitals  City 
outpatient 
LL HCFs Total 
1 Stock room inventory 252 36 26 314 
2 HCF observations 36 18 26 80 
3 Observations of injections or phlebotomy  2016 288 104 2408 
4 Injection administrator interviews  252 36 26 314 
5 Interviews with supervisors of injection 
administrators 
252 36 26 80 
6 Waste management interviews 36 18 26 80 
7 Patients 864 144 52 1060 
 
Table 3c: Target Population Sample for Uzbekistan   
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 # Target Population 
Sample size 
Hospitals  City 
outpatient 
LL HCFs Total 
1 Stock room inventory 455 8 6 469 
2 HCF observations 65 4 6 75 
3 Observations of injections or phlebotomy  3640 64 24 3728 
4 Injection administrator interviews  455 8 6 469 
5 Interviews with supervisors of injection 
administrators 
455 8 6 75 
6 Waste management interviews 65 4 6 75 
7 Patients 1560 32 12 1604 
 
Table 3d: Target Population Sample for Tajikistan   
 
 
 # Target Population 
Sample size 
Hospitals  City 
outpatient 
LL HCFs Total 
1 Stock room inventory 196 50 53 299 
2 HCF observations 28 25 53 106 
3 Observations of injections or phlebotomy  1624 400 212 2236 
4 Injection administrator interviews  196 50 53 299 
5 Interviews with supervisors of injection 
administrators 
196 50 53 299 
6 Waste management interviews 28 25 53 106 
7 Patients 672 200 106 978 
 
 
 
4.6. Data Collection 
 
Teams will visit an average of 1 hospital or 2 lower-level facilities per day. The 
estimated number of days for data collection in the field for each country is as 
follows: 
 
This activity will be carried out using the assessment tools adapted to the context 
of the health system. The assessment tools are questionnaires with 6 
components or ‘‘Sections’’ that relate to specific intervention areas of injection 
safety. (See Appendices 3 under separate cover.) These sections are:  
 
• Inventory/stock rooms: Section 1 
• Observations of health facilities and waste management: Section 2 
• Observations of injection practices: Section 3 
• Interviews of injection providers: Section 4 
• Interviews with supervisors of injection providers: Section 5 
• Interviews with waste management staff: Section 6 
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• Interviews of  patients: Section 7  
 
Data will be collected by 12 people. There will be 4 teams consisting of, on 
average, 3 people consisting of 2 data collectors and 1 team leader. Generally, 
there will be one data collection team per 2 districts.  
   
4.6.1 Respondent selection 
 
Respondents will be selected according to the specific criteria 
detailed below: 
• In each department, if more than one HCW provides procedures the 
provider who gives the most injections will be selected for interview 
(“injection administrator”). The data collector will ask the individual health 
care workers for their permission to be observed prior to the interview.  
• If the injection provider who was interviewed has a supervisor in the 
department at the time of the survey, this person is to be selected for the 
supervisor interview. Head nurse of observed department would be 
preferable as supervisor for interview. In case the head nurse is not 
available, the head doctor could be interviewed as a supervisor. If the 
provider does not have a supervisor, another injection provider will be 
interviewed; or if none is available at the time of the survey, the questions 
are asked of the injection provider.   
• Only one waste handler is to be interviewed in each facility .The surveyor 
should select the waste handler who is the primary person in charge of 
managing health care waste. 
• Patients in departments in hospital will be selected randomly from the list 
of patients hospitalized into observing department, excluding ICU patients. 
In city outpatient clinics and LL HCF any patient in turn will be selected for 
interview. In case if only children are receiving vaccinations at time of 
observation, their relatives who are accompanying them will be selected 
for interview.  
 
4.6.2 Confidentiality protections 
 
To ensure confidentiality protection prior to conducting interviews, an informed 
consent will be read to the respondent and signed by the interviewer with no 
health care worker or patient identifying information. There is potential risk to the 
participant from signing a consent form. Potentially risky practices will be 
observed and the consent form will be the only objective link of participants to 
having participated in the assessment. Thus, we believe a waiver of signed 
consent is justified. If the person refuses to participate, the data collector will 
accept the refusal and record that a potential participant has declined. Also 
participants will have a clear choice to leave the interview at any time. Data 
collectors will ensure that HCW’s or patient’s interviews are conducted in a 
private setting where they will not be overheard by facility health care staff or 
anyone else. Data collection will involve adults only and data collected will not be 
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identifiable. To minimize risk to the participant, data collected will not include any 
identifying information and will only be handled by the study team.  Data will be 
presented publicly in aggregate form (by district, by type of facility, and by 
department in hospitals.) Results presented in the report are not linked to 
individual facilities where data are collected, so they are not traceable to 
individual respondents. (See Appendix 4 for Sample Informed Consent Forms).  
 
 
4.6.3 Other ethical concerns/issues 
 
We will take ensure risks to participants are minimized and 
information is kept confidential such as holding interviews in a 
private setting where they will not be overheard by other facility 
health care staff, supervisors, or anyone else. Specific risks and 
protections are detailed below: 
 
Health care workers that are observed giving injections or conducting 
phlebotomy will also be interviewed to find out if they have ever had a needle 
stick injury, what diseases they are aware of that can be transmitted by needle 
stick injuries, and their HBV vaccination status. This activity is similar to 
supervisory visits and the risk to the employment position of the respondent is 
minimal. Data collectors will not collect the names or other information to identify 
the health care worker being interviewed or observed and will ask individual 
HCWs for their permission to observe procedures. If HCWs experience a needle 
stick injury during the observation or disclose during the interview that one was 
suffered within the preceding seven   days (arbitrarily determined by the 
likelihood of successful interventions, e.g., HBV vaccination, ART prophylaxis, 
patient being accessible) the study team will be able to provide participants 
information and correct referrals for post-exposure prophylaxis (PEP) within the 
facility where the health worker is currently employed. This is to ensure that if a 
HCW reports a needle stick or other occupational exposure to BBP, they can be 
quickly referred to the appropriate person or service. This arrangement will be 
made before research activities take place in collaboration with the health facility 
infection prevention and control specialist. .  
• Surveyors will be trained to tactfully interrupt any health care workers who 
may be about to re-use syringes and needles prior to them endangering 
patients; training will be provided on when to intervene. In case of such 
intervention no more injections will be observed for this healthcare worker. 
In this case, observation of another HCW will begin to complete 
observation of the required number of procedures.     
• Patients receiving injections may need to remove clothing to expose 
injection sites. The possible risks of embarrassment or worry are not 
expected to outweigh the potential benefits of the study.  Before beginning 
the observation, data collectors will inform the patient that a survey is 
being conducted during which the health care worker will be observed 
giving an injection and ask for their permission.  
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• Supervisors are interviewed about documentation and logistical issues 
related to injection equipment.  These questions are not sensitive or 
potentially stigmatizing, and the risk to their position is minimal. Data 
collectors will not collect the names or other information to identify the 
supervisor being interviewed.    
• Waste handlers are asked about waste handling practices, training, 
protective equipment, etc. This activity is similar to supervisory visits and 
the risk to their positions is minimal. Data collectors will not collect the 
names or other information to identify the waste handler being 
interviewed.  
• Feedback will be given to facility administrators about hazards needing 
improvement and strengths without providing information that would allow 
individuals to be identified. Hospital administrators will be informed prior to 
data collection activities that feedback will not include any information that 
could identify an individual (including department name). 
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Table 4: Tentative Schedule for Data Collection 
 
Day Date Activities Comments 
Day 1     
Day 2    
Day 3  
 
 
Day 4  
 
 
Day 5  
 
 
Day 6    
Day 7  
 
 
Day 8  
 
 
Day 9     
Day 10    
Day 11    
Day 12    
Day 13    
Day 14    
Day 15    
 
 
4.7. Organization and Coordination of the Data Entry and Analysis 
 
All collected data will belong to the MoH and MoH will share these data with the 
CDC. Supervisors of the survey teams will check forms prior to leaving a facility 
to make sure entries are legible and forms are complete. Nobody except 
assessors, CAAP and CDC /CAR staff will have access to collected data.  
 
Data will be captured on the assessment tools and entered into a data entry 
program in Epi Info. The data collected will be codified prior to data entry, 
especially in regards to open-ended questions. The data will be analyzed by 
comparing facility-level indicators over time and when possible between districts 
using Epi Info.  
 
The survey questionnaires will be returned to the CDC office for data entry. The 
data entry staff will be hired by the CDC/CAR.  Access to the dataset will be 
limited to the data entry staff and CDC epidemiologist who will oversee all 
aspects of data coding, entry, cleaning and reporting.   The data entry staff will 
consist of 2 people, independently creating two databases which will be merged 
to identify discrepancies. The data entry program will also have control checks to 
ensure proper skips and logical values. Database will be protected by password. 
This password will be available for data entry staff as well as CDC staff 
responsible for data analysis. As disaster recovery measure data entered in the 
computer will be backed up daily.  
 
Hard copies of the observations and interviews will be stored in a locked cabinet. 
The original data collection forms will be retained for three years following 
completion of data entry, and then shredded  Electronic database will be kept 
44 
 
during three year period till analysis and report is prepared and presented to the 
MoH.  
 
Once that process is finished, the CDC specialist will send the data files and draft 
report to CDC/Atlanta staff for review.    
 
4.8. Analysis Plan 
 
The analysis will be used to provide the types of expected results as described in 
Section 3 of this protocol. The general analysis plan will be provided to the 
person responsible for data analysis (See Appendix 5 under separate cover.)  
This plan may be expanded as needed to accommodate additional questions 
which are added to the questionnaires or areas of interest to partners in country. 
The data will be analyzed to the extent possible:  
• By type of facility (hospital vs. lower level) 
• By hospital service department (medicine, pediatrics, ob-gyn, etc.) 
• By type of injection (vaccination, curative, diagnostic) 
•  Per type of injection (IM, IV injection, IV infusion, phlebotomy)  
   
For the evaluation component of the study in which we compare the likelihood of 
observing unsafe injections pre- and post- intervention, we will use a frailty model 
(a proportional hazards model with random effects terms).  In this model 
individuals are considered to have been observed over time, with time being the 
injection number and a “death” is delivering the first unsafe injection5.  In this 
model sites are handled as the random effects term and the indicator for pre- or 
post- intervention is consider a fixed effect.  These models will be fit looking at 
each type of injection separately. 
 
4.9. Preparation of the Assessment Report 
 
The report will be written based on the results of the database analysis. It will be 
prepared by the CDC/CAR specialists, and will undergo technical review to 
ensure the overall quality of the report.  The report will follow the general outline 
provided to the analyst and will cover the different topics mentioned in the 
analysis plan. [See Appendix 5 for sample table of contents and Appendix 6 
(under separate cover) for analysis plan.]  
 
4.10. Dissemination of the Results of the Assessment 
 
The results and the assessment will be presented as a report combined with 
information from other countries at a regional workshop for all countries of CAR.  
This workshop will include national decision makers, the survey team, directors 
of large facilities where assessments were conducted and other national or 
                                                 
5
 Injections are considered as deaths in this model in that once an unsafe injection is observed, the observer 
may intervene and the health care worker referred for training.  In this situation no further injections will be 
observed. 
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international agencies with an interest in the results.  Results to be presented will 
be shown as aggregated results by CAR region, district or by type of facility (such 
as grouping all hospitals together, for example).  Data from individual countries 
will be presented only if there is preceding approval from the Ministry of Health of 
each country to do so and countries will not be announced; each country will be 
given a number -1, 2, 3 and 4. If one country objects, then all data will be 
aggregated.   
 
The final country-specific survey report will be shared with MOH. MOH will 
decide the sharing mechanism with other counterparts. Results may also be 
presented at conferences as lessons learned in the following areas (1) need for 
changing the behavior of health care workers to ensure safe injection practices 
through capacity building, behavior change and communications, and policy 
interventions; (2) ensuring the availability of safe injection equipment and 
supplies through procurement and logistics interventions; and (3) managing 
health care waste safely and appropriately; (4) reduction/elimination of 
unnecessary injections  
 
4.11. Human Resources  
 
The protocol was written by CDC/CAR and CDC/Atlanta staff, CV’s can be found 
in Appendix 7.  
 
Local consultants will be hired as a General Coordinator of the study, supervisors 
for teams, data collectors for teams, and data entry clerks.  The General 
Coordinator, supervisors, and data collectors are usually doctors or nurses. 
Consultant CVs will be made available and will be provided to the CAAP and 
CDC/CAR offices and, through a collegial process guided by consensus, 
individuals will be selected. 
  
Data collectors will be trained in a classroom setting with an introduction to 
Injection safety and waste management concepts.  This training will include a 
detailed review of the entire questionnaire including all instructions and skips.  
Practice sessions will be held at a local hospital and lower level facility which are 
not included in the sample.   This visit provides an opportunity to standardize the 
approach to data collection, to provide feedback on the performance of data 
collectors, and to field test the questionnaires in the local context.  In the first few 
days of the actual data collection, data collectors will receive close support from 
technical advisors and hired supervisors to ensure good quality data and to help 
address any issues that arise. Data collectors are to be supervised throughout 
data collection by supervisors; they should be provided with contact information 
to have immediate access to a supervisor as needed during data collection.  
 
 
Table 4: Tentative Composition of the Data Collection Teams per country 
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AREA 
 
Team Composition 
 
#  
People 
#  
Teams 
 
Total  
 
 
Coordination 
General Coordinator  
( consultant) 
  
 
1 
 
 
 
__ 
 
1 
 
  
Supervision Supervisors 4 4 4 
Data Collection 
- Inventory Management  
- Observations of Waste 
Management 
- Observations of Injection 
Administration 
- Interviews of providers, 
supervisors, waste handlers and 
patients 
 
Data collectors 
12 4-6 12 
 
Support Activities 
 
Field Guide (local) 
 
1 TBD 
  
1 
Data Entry 
 
Data entry consultants  2 __ 2 
 
Analysis of the Data 
  Epidemiologist CDC/CAR   
1 
__  
1 
 
TOTAL 
15 
 
 
4.12. Material Resources 
 
• Vehicles 
 
It will be necessary to mobilize a vehicle to transport each team of data 
collectors and its supervisor to the districts and within each district. CAAP 
is responsible for teams’ transportation.  
 
• Data Collection Tools - See under separate cover (Appendix 3).  
 
• Office Supplies 
The data collectors will be given the following materials: 
- Pencil, pen, eraser 
- Folders for carrying completed forms and blank forms  
- Memo pad for notes on problems to discuss with their supervisors 
- Copies of the questionnaires 
- Copies of consent forms  
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• Fuel 
The fuel allocation necessary for travel of the assessment and 
coordination teams from the capital to the districts and within the districts 
will be reimbursed by CAAP.  
 
• Telecommunications Equipment 
Always mobile telephone cards for communication between teams of data 
collectors and supervisors and between the coordination team and the 
supervisors. Telephone cards will be reimbursed by CAAP.  
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